CNS disorders - Current treatment options and the prospects for advanced therapies

Drug Development and Industrial Pharmacy

Volumn 34, Issue 11, 2008, Pages 1141-1167

  DiNunzio, James C ^a   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Alzheimer's disease; Animal models; Blood brain barrier; Central nervous system; Depression; Drug delivery; Epilepsy; Multiple sclerosis; Neuropathic pain; Parkinson's disease

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; BETA1A INTERFERON; CHLORPROMAZINE; CITALOPRAM; CLORAZIL; CLOZAPINE; DANTROLENE; DONEPEZIL; DULOXETINE; ESCITALOPRAM; ETIRACETAM; FELBAMATE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; GALANTAMINE; GLATIRAMER; HARKOSERIDE; INDALPINE; INTERFERON BETA SERINE; JWB 1 84 1; LF 15 0195; LIDOCAINE; MAPROTILINE; MEMANTINE; MILNACIPRAN; NATALIZUMAB; NT 1505; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; PNU 282987; PREGABALIN; QUETIAPINE; RETIGABINE; RISPERIDONE; RIVASTIGMINE; SB 399885; SERTRALINE; TACRINE; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZIMELDINE; ZIPRASIDONE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG RESEARCH; EPILEPSY; HUMAN; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NONHUMAN; PATHOGENESIS; PRODUCT DEVELOPMENT; REVIEW; SCHIZOPHRENIA;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; TECHNOLOGY, PHARMACEUTICAL;

EID: 54449093310     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802020536     Document Type: Review

References (167)

1. Abilify® (aripiprazole) - A Treatment for Bipolar Disorder and Schizophrenia. Retrieved January 1, 2008, 2008, from http://www.abilify.com
2. Albert, M. S. (2007). Changing the trajectory of cognitive decline? N. Engl. J. Med., 357(5), 502-503.
3. Aricept® (donepezil HCI) - Official Site - Aricept - Alzheimer's. Retrieved January 1, 2008, 2008, from http://www.aricept.com/
4. Azmin, M. N., Stuart, J. F. B., & Florence, A. T. (1985). The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother. Pharmacol., 14(3), 238-242.
5. Bachurin, S. O., Beznosko, B. K., Grigoriev, V. V., Serkova, T. A., Palyulin, V. A., & Zefirov, N. S. (2007). Design of novel europrotective NMDA-Receptor Ligands. Frontiers in CNS and Oncology Medicinal Chemistry, 7-9.
6. Batrakova, E. V., & Kabanov, A. V. (2007). Strategies to Overcome the Blood-Brain Barrier. In E. Touitou, & B. W. Barry (Eds.), Enhancement in drug delivery (pp. 593-614). Boca Raton: CRC Press.
7. Baulac, S., Huberfeld, G., Gourfinkel-An, I., Mitropoulou, G., Beranger, A., Prud'homme, J. -F., Baulac, M., Brice, A., Bruzzone, R., & LeGuern, E. (2001). First genetic evidence of GABAA receptor dysfunction in epilepsy: A mutation in the γ2-subunit gene. Nat. Genet., 28(1), 46-48.
8. Benbadis, S. R. (2001). Epileptic seizures and syndromes. Neurol. Clin., 19(2), 251-270.
9. Bennett, G. J., & Xie, Y. K. (1988). A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain, 33(1), 87-107.
10. BETASERON.com | Your Resource for Information on Multiple Sclerosis and BETASERON Treatment. Retrieved January 1, 2008, 2008, from http://www.betaseron. com
11. Bettelli, E. (2007). Building different mouse models for human MS. Ann. N.Y. Acad. Sci., 1103(How Do We Best Employ Animal Models for Type 1 Diabetes and Multiple Sclerosis?), 11-18.
12. Bettelli, E., Pagany, M., Weiner, H. L., Linington, C., Sobcl, R. A., & Kuchroo, V. K. (2003). Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med., 197(9), 1073-1081.
13. Biziere, K., Worms, P., Kan, J. P., Mandel, P., Garattini, S., & Roncucci, R. (1985). Minaprine, a new drug with antidepressant properties. Drugs Exp. Clin. Res., 11(12), 831-840.
14. Boado, R. J., Zhang, Y., Zhang, Y., & Pardridge, W. M. (2007). Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular trojan horse for delivery across the human blood-brain barrier. Biotechnol. Bioeng., 97(6), 1376-1386.
15. Boado, R. J., Zhang, Y., Zhang, Y., Xia, C. -F., & Pardridge, W. M. (2007). Fusion Antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and a? fibril disaggregation. Bioconjug. Chem., 18(2), 447-455.
16. Bolton, C. (2007). The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis. Inflammopharmacology, 15(5), 183-187.
17. Bonina, F., Puglia, C., Rimoli, M. G., Melisi, D., Boatto, G., Nieddu, M., Calignano, A., La Rana, G., & De Caprariis, P. (2003). Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: Synthesis, pharmacological activity and in vitro stability studies. J. Drug Target., 11(1), 25-36.
18. Boot, J. R., Brace, G., Delatour, C. L., Dezutter, N., Fairhurst, J., Findlay, J., Gallagher, P. T., Hoes. I., Mahadevan, S., Mitchell, S. N., Rathmell, R. E., Richards, S. J., Simmonds, R. G., Wallace, L., & Whatton, M. A. (2004). Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg. Med. Chem. Lett., 14(21), 5395-5399.
19. Borsini, F. (1995). Role of the serotonergic system in the forced swimming test. Neurosci. Biobehav. Rev., 19(3), 377-395.
20. Cabarrocas, J., Cassan, C., Magnusson, F., Piaggio, E., Mars, L., Derbinski, J., Kyewski, B., Gross, D. A., Salomon, B. L., Khazaie, K., Saoudi, A., & Liblau, R. S. (2006). Foxp3+ CD25+ regulatory T cells specific for a neo-self-antigen develop at the double-positive thymic stage. Proc. Natl. Acad. Sci. U. S. A., 103(22), 8453-8458.
21. Capuano, B., Crosby, I. T., & Lloyd, E. J. (2002). Schizophrenia: Genesis, receptorology and current therapeutics. Curr. Med. Chem., 9(5), 521-548.
22. Cassan, C., & Liblau, R. S. (2007). Immune tolerance and control of CNS autoimmunity: From animal models to MS patients. J. Neurochem., 100(4), 883-892.
23. Castner, S. A., Goldman-Rakic, P. S., & Williams, G. V. (2004). Animal models of working memory: Insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology, 174(1), 111-125.
24. Chang, B. S., & Lowenstein, D. H. (2003). Epilepsy. N. Engl. J. Med., 349(13), 1257-1266.
25. Chopineau, J., Robert, S., Fenart, L., Cecchelli, R., Lagoutte, B., Paitier, S., Dehouck, M. P., & Domurado, D. (1998). Monoacylation of ribonuclease A enables its transport across an in vitro model of the blood-brain barrier. J. Control. Release, 56(1-3), 231-237.
26. Clinical Pharmacology - Drug Product Monographs (Publication (2007)). Retrieved December 31, 2007, from Gold Standard: Coloma, M. J., Lee, H. J., Kurihara, A., Landaw, E. M., Boado, R. J., Morrison, S. L., & Pardridge, W. M. (2000). Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res., 17(3), 266-274.
27. Conte, U., & Maggi, L. (2000). A flexible technology for the linear, pulsatile and delayed release of drugs, allowing for easy accommodation of difficult in vitro targets. J. Control. Release, 64(1-3), 263-268.
28. Copaxone® - Multiple sclerosis therapy helping you manage your relapsing-remitting MS symptoms. Retrieved January 1, 2008, 2008, from http://www.copaxone.com
29. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261(5123), 921-923.
30. Costall, B., Naylor, R. J., & Nohria, V. (1980a). Dopamine agonist and antagonist action after mesolimbic denervation. Br. J. Pharmacol., 70(1), 49P-50P.
31. Costall, B., Naylor, R. J., & Nohria, V. (1980b). On the importance of mesolimbic mechanisms for the control of apomorphine induced climbing behavior in the mouse. Br. J. Pharmacol., 68(1), 175P-176P.
32. Costigan, M., Befort, K., Karchewski, L., Griffin, R. S., D'Urso, D., Allchorne, A., Sitarski, J., Mannion, J. W., Pratt, R. E., & Woolf, C. J. (2002). Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci., 3(16).
33. Cryan, J. F., & Holmes, A. (2005). Model organisms: The ascent of mouse: Advances in modeling human depression and anxiety. Nat. Rev. Drug Discov., 4(9), 775-790.
34. Cryan, J. F., Mombereau, C., & Vassout, A. (2005). The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev., 29(4-5), 571-625.
35. Cryan, J. F., & Slattery, D. A. (2007). Animal models of mood disorders: Recent developments. Curr. Opin. Psychiatry, 20(1), 1-7.
36. Cryan, J. F., Valentino, R. J., & Lucki, I. (2005). Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev., 29(4-5), 547-569.
37. Cymbalta.com. Retrieved January 1, 2008, 2008, from http://www.cymbalta. com
38. Decosterd, I., & Woolf, C. J. (2000). Spared nerve injury: An animal model of persistent peripheral neuropathic pain. Pain, 87(2), 149-158.
39. Denora, N., Laquintana, V., Lopedota, A., Serra, M., Dazzi, L., Biggio, G., Pal, D., Mitra, A. K., Latrofa, A., Trapani, G., & Liso, G. (2007). Novel L-Dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety. Pharm. Res., 24(7), 1309-1324.
40. Detke, M. J., Rickels, M., & Lucki, I. (1995). Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology, 121(1), 66-72.
41. Dorado, P., Peñas-Lledó, E. M., González, A. P., Cáceres, M. C., Cobaleda, J., & Llerena, A. (2007). Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele. Fundam. Clin. Pharmacol., 21(4), 451-453.
42. Duplan, V., Beriou, G., Heslan, J. -M., Bruand, C., Dutartre, P., Mars, L. T., Liblau, R. S., Cuturi, M. C., & Saoudi, A. (2006). LF 15-0195 Treatment Protects against Central Nervous System Autoimmunity by Favoring the Development of Foxp3-Expressing Regulatory CD4 T Cells. J. Immunol., 176(2), 839-847.
43. Dworkin, R. H., Backonja, M., Rowbotham, M. C., Allen, R. R., Argoff, C. R., Bennett, G. J., Bushnell, M. C., Farrar, J. T., Galer, B. S., Haythornthwaite, J. A., Hewitt, D. J., Loeser, J. D., Max, M. B., Saltarelli, M., Schmader, K. E., Stein, C., Thompson, D., Turk, D. C., Wallace, M. S., Watkins, L. R., & Weinstein, S. M. (2003). Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Arch. Neurol., 60(11), 1524-1534.
44. El Yacoubi, M., & Vaugeois, J. -M. (2007). Genetic rodent models of depression. Curr. Opin. Pharmacol., 7(1), 3-7.
45. Ellison, M. D., Povlishock, J. T., & Merchant, R. E. (1987). Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res., 47(21), 5765-5760.
46. Escayg, A., MacDonald, B. T., Meisler, M. H., Baulac, S., Huberfeld, G., An-Gourfinkel, I., Brice, A., LeGuern, E., Moulard, B., Chaigne, D., Buresi, C., & Malafosse, A. (2000). Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat. Genet., 24(4), 343-345.
47. Exelon® Patch. Retrieved January 1, 2008, 2008, from http://www.exelonpatch.com
48. Fischer, H., Gottschlich, R., & Seelig, A. (1998). Blood-brain barrier permeation: Molecular parameters governing passive diffusion. J. Membr. Biol., 165(3), 201-211.
49. Fox, A., Eastwood, C., Gentry, C., Manning, D., & Urban, L. (1999). Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain, 81(3), 307-316.
50. Freedman, R. (2003). Schizophrenia. N. Engl. J. Med., 349(18), 1738-1749.
51. Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., & Gillespie, F., Guido, T., Hagopian, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, H., Vitale, J., Wadsworth, S., Wolozin, B., & Zhao, J. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F ?-amyloid precursor protein. Nature, 373(6514), 523-527.
52. Ghiso, J., & Frangione, B. (2002). Amyloidosis and Alzheimer's disease. Adv. Drug Deliv. Rev., 54(12), 1539-1551.
53. Goel, N., & Bale, T. L. (2007). Identifying early behavioral and molecular markers of future stress sensitivity. Endocrinology, 148(10), 4585-4591.
54. Gold, R., Linington, C., & Lassmann, H. (2006). Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain, 129(Part 8), 1953-1971.
55. Hanig, J. P., Morrison, J. M., Jr., & Krop, S. (1972). Ethanol enhancement of blood-brain barrier permeability to catechol amines in chicks. Eur. J. Pharmacol., 18(1), 79-82.
56. Higuera, E. S., & Luo, Z. D. (2004). A rat pain model of vincristine-induced neuropathy. Methods Mol. Med., 99, 91-98.
57. Hirst, W. D., Stean, T. O., Rogers, D. C., Sunter, D., Pugh, P., Moss, S. F., Bromidge, S. M., Riley, G., Smith, D. R., Bartlett, S., Heidbreder, C. A., Atkins, A. R., Lacroix, L. P, Dawson, L. A., Foley, A. G., Regan, C. M., & Upton, N. (2006). SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol., 553(1-3), 109-119.
58. Hohlfeld, R., & Wekerle, H. (2001). Immunological update on multiple sclerosis. Curr. Opin. Neurol., 14(3), 299-304.
59. Hu, M., Schurdak, M. E., Puttfarcken, P. S., El Kouhen, R., Gopalakrishnan, M., & Li, J. (2007). High content screen microscopy analysis of Aβ.1-42-induced neurite outgrowth reduction in rat primary cortical neurons: Neuroprotective effects of α7 neuronal nicotinic acetylcholine receptor ligands. Brain Res., 1151, 227-235.
60. In the treatment of mild to moderate dementia of Alzheimers Disease. Retrieved January 1, 2008, 2008, from http://www.razadyneer.com
61. Ishiyama, T., Tokuda, K., Ishibashi, T., Ito, A., Toma, S., & Ohno, Y. (2007). Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol., 572(2-3), 160-170.
62. Jallouli, Y., Paillard, A., Chang, J., Sevin, E., & Betbeder, D. (2007). Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int. J. Pharm., 344(1-2), 103-109.
63. Kabanov, A. V., & Gendelman, H. E. (2007). Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci., 32(8-9), 1054-1082.
64. Kelleher, J. P., Centorrino, F., Albert, M. J., & Baldessarini, R. J. (2002). Advances in atypical antipsychotics for the treatment of schizophrenia: New formulations and new agents. CNS Drugs, 16(4), 249-261.
65. Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., Wittchen, H. U., Kendler, K. S. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry, 51(1), 8-19.
66. Kieseier, B. C., & Hartung, H. -P. (2007). Interferon-β and neuroprotection in multiple sclerosis - facts, hopes and phantasies. Exp. Neurol., 203(1), 1-4.
67. Kim, S. H., & Chung, J. M. (1992). An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain, 50, 355-363.
68. Kobiler, D., Lustig, S., Gozes, Y., Ben-Nathan, D., & Akov, Y. (1989). Sodium dodecyl sulfate induces a breach in the blood-brain barrier and enables a West Nile virus variant to penetrate into mouse brain. Brain Res., 496(1-2), 314-316.
69. Koe, B. K., Weissman, A., Welch, W. M., & Browne, R. G. (1983). Sertraline, 1S,4 Smethyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1- naphthylamine, a new uptake inhibitor with selectivity for serotonin. J. Pharmacol. Exp. Ther., 226(3), 686-700.
70. Koistinaho, M., & Koistinaho, J. (2005). Interactions between Alzheimer's disease and cerebral ischemia - focus on inflammation. Brain Res. Rev., 48(2), 240-250.
71. Kostopoulos, G. K. (2001). Involvement of the thalamocortical system in epileptic loss of consciousness. Epilepsia, 42(Suppl. 3), 13-19.
72. Kozlova, N. O., Bruskovskaya, I. B., Melik-Nubarov, N. S., Yaroslavov, A. A., & Kabanov, V. A. (1999). Catalytic properties and conformation of hydrophobized .alpha.-chymotrypsin incorporated into a bilayer lipid membrane. FEBS Lett., 461(3), 141-144.
73. Krauze, M. T., Saito, R., Noble, C., Bringas, J., Forsayeth, J., Mcknight, T. R., Park, J., & Bankiewicz, K. S. (2005). Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp. Neurol., 196(1), 104-111.
74. Kreuter, J. (2007). Nanoparticles - a historical perspective. Int. J. Pharm., 331(1), 1-10.
75. Krewson, C. E., Klarman, M. L., & Saltzman, W. M. (1995). Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res., 680(1, 2), 196-206.
76. Kumar, V., & Banker, G. S. (1996). Target-oriented drug delivery systems. In G. S. Banker & C. T. Rhodes (Eds.), Modern pharmaceutics (Vol. 72). New York: Marcel Dekker.
77. Kuo, Y. -C., & Su, F. -L. (2007). Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm., 340(1-2), 143-152.
78. Kusuhara, H., & Sugiyama, Y. (2001a). Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discovery Today, 6(3), 150-156.
79. Kusuhara, H., & Sugiyama, Y. (2001b). Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug Discov. Today, 6(4), 206-212.
80. Kwan, P., & Brodie, M. J. (2000). Early identification of refractory epilepsy. N. Engl. J. Med., 342(5), 314-319.
81. Levin, V. A. (1980). Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem., 23(6), 682-684.
82. Lidoderm® (Lidocaine Path 5%) - Targets the Lingering Pain After the Shingles. Retrieved January 1, 2008, 2008, from http://www.lidoderm.com/
83. Lieberman, J. A., Stroup, S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., Hsiao, J. K., & Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 353(12), 1209-1223.
84. Liu, C. -N., Devor, M., Waxman, S. G., & Kocsis, J. D. (2002). Subthreshold oscillations induced by spinal nerve injury in dissociated muscle and cutaneous afferents of mouse DRG. J. Neurophysiol., 87(4), 2009-2017.
85. Liu, X., & Gershenfeld, H. K. (2003). An exploratory factor analysis of the Tail Suspension Test in 12 inbred strains of mice and an F2 intercross. Brain Res. Bull., 60(3), 223-231.
86. Lopez-Rubalcava, C., & Lucki, I. (2000). Strain differences in the behavioural effects of antidepressant drugs in the rat forced swimming test. Neuropsychopharmacology, 22, 191-199.
87. Lucki, I., Dalvi, A., & Mayorga, A. J. (2001). Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology, 155(3), 315-322.
88. Luszczki, J. J., Jankiewicz, K., Jankiewicz, M., & Czuczwar, S. J. (2007). Influence of aminophylline on the anticonvulsive action of gabapentin in the mouse maximal electroshock seizure threshold model. J. Neural Transm., 114(12), 1539-1545.
89. Maier, S. F., & Watkins, L. R. (2005). Stressor controllability and learned helplessness: The roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci. Biobehav. Rev., 29(4-5), 829-841.
90. Malinge, M., Bourin, M., Colombel, M. C., & Larousse, C. (1988). Additive effects of clonidine and antidepressant drugs in the mouse forced-swimming test. Psychopharmacology, 96(1), 104-109.
91. Mann, J. J. (2005). The medical management of depression. N. Engl. J. Med., 353(17), 1819-1834.
92. Masliah, E., Sisk, A., Mallory, M., Mucke, L., Schenk, D., & Games, D. (1996). Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F .beta.-amyloid precursor protein and Alzheimer's disease. J. Neurosci., 16(18), 5795-5811.
93. McArthur, R., & Borsini, F. (2006). Animal models of depression in drug discovery: A historical perspective. Pharmacol. Biochem. Behav., 84(3), 436-452.
94. McFarland, H. F., & Martin, R. (2007). Multiple sclerosis: A complicated picture of autoimmunity. Nat. Immunol., 8(9), 913-919.
95. McKenna, P. J. (1987). Pathology, phenomenology and the dopamine hypothesis of schizophrenia. Br. J. Psychiatry, 151, 288-301.
96. Merkus, F. W. H. M., & van den Berg, M. P. (2007). Can nasal drug delivery bypass the blood-brain barrier? Questioning the direct transport theory. Drugs R D, 8(3), 133-144.
97. Merlini, G., & Bellotti, V. (2003). Molecular Mechanisms of Amyloidosis. N. Engl. J. Med., 349(6), 583-596.
98. Mesens, J., Rickey, M. E., & Atkins, T. J. (2003). United States of America Patent No. US 6,544,559 B2. U. S. P. T. Office.
99. Miguel-Hidalgo, J. J., & Rajkowska, G. (2002). Morphological brain changes in depression: Can antidepressants reverse them? CNS Drugs, 16(6), 361-372.
100. Mogilnicka, E., Czyrak, A., & Maj, J. (1987). Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test; antidepressants facilitate nifedipine action. Eur. J. Pharmacol., 138(3), 413-416.
101. Mogilnicka, E., Czyrak, A., & Maj, J. (1988). BAY K 8644 enhances immobility in the mouse behavioral despair test, an effect blocked by nifedipine. Eur. J. Pharmacol., 151(2), 307-311.
102. Monotherapy Treatment for MS. Retrieved January 1, 2008, 2008, from http://www.tysabri.com/tysbProject/tysb.portal
103. Namenda Alzheimer's Symptoms Treatment - Namenda.com. Retrieved January 1, 2008, 2008, from http://www.namenda.com
104. Narrow, W. E., Rae, D. S., Robins, L. N., & Regier. D. A. (2002). Revised prevalence estimates of mental disorders in the United States: Using a clinical significance criterion to reconcile 2 surveys' estimates. Arch. Gen. Psychiatry, 59(2), 115-123.
105. Natalizumab (marketed as Tysabri) Information. Retrieved January 1, 2008, 2008, from http://www.fda.gov/cder/drug/infopage/natalizumab/default.htm
106. Neuwelt, E. A. (2004). Mechanisms of disease: The blood-brain barrier. Neurosurgery, 54(1), 131-142.
107. Ochi, H., Abraham, M., Ishikawa, H., Frenkel, D., Yang, K., Basso, A. S., Wu, H., Chen, M. L., Gandhi, R., Miller, A., Maron, R., & Weiner, H. L. (2006). Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25-LAP+T cells. Nat. Med., 12(6), 627-635.
108. The Official ZYPREXA Olanzapine Site. Retrieved January 1, 2008, 2008, from http://www.zyprexa.com
109. Overstreet, D. H., Pucilowski, O., Rezvani, A. H., & Janowsky, D. S. (1995). Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Psychopharmacology, 121(1), 27-37.
110. Pardridge, W. M. (2002a). Targeting neurotherapeutic agents through the blood-brain barrier. Arch. Neurol., 59(1), 35-40.
111. Pardridge, W. M. (2002b). Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov. Today, 7(1), 5-7.
112. Pardridge, W. M. (2007a). Blood-brain barrier delivery. Drug Discov. Today, 12(1/2), 54-61.
113. Pardridge, W. M. (2007b). Drug targeting to the brain. Pharm. Res., 24(9), 1733-1744.
114. Paxil CR, an SSRI, treats depression, panic disorder, social anxiety disorder, PMDD. Retrieved January 1, 2008, 2008, from http://www.paxilcr.com
115. Peracchia, M. T., Vauthier, C., Desmaële, D., Gulik, A., Dedieu, J. -C., Demoy, M., d'Angelo, J., & Couvreur, P. (1998). PEGylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm. Res., 15(4), 550-556.
116. Pharmaceutical Executive Staff. (2007). The Pharm Exec 50: Holding Pattern. Pharmaceutical Executive, May, 98-110.
117. Pryce, C. R., Ruedi-Bettschen, D., Dettling, A. C., Weston, A., Russig, H., Ferger, B., & Feldon, J. (2005). Long-term effects of early-life environmental manipulations in rodents and primates: Potential animal models in depression research. Neurosci. Biobehav. Rev., 29(4-5), 649-674.
118. Raja, S. N., & Haythornthwaite, J. A. (2005). Combination therapy for neuropathic pain - which drugs, which combination, which patients? N. Engl. J. Med., 352(13), 1373-1375.
119. Ransohoff, R. M. (2007). Natalizumab for multiple sclerosis. N. Engl. J. Med., 356(25), 2622-2629.
120. Rao, H., Gillihan, S. J., Wang, J., Korczykowski, M., Sankoorikal, G. M. V., Kaercher, K. A., Brodkin, E. S., Detre, J. A., & Farah, M. J. (2007). Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol. Psychiatry, 62(6), 600-606.
121. Rebif. Retrieved January 1, 2008, 2008, from http://www.mslifelines.com/ rebif/index.jsp
122. Reneric, J. -P., & Lucki, I. (1998). Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology, 136(2), 190-197.
123. Risperdal. Retrieved January 2008, 2008, from http://www.risperdal.com
124. RISPERDAL CONSTA - For Healthcare Providers. Retrieved January 1, 2008, 2008, from http://risperdalconsta.com/risperdalconsta/hcp/index_hcp.html
125. Rockenstein, E., Crews, L., & Masliah, E. (2007). Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv. Drug Deliv. Rev., 59(11), 1093-1102.
126. Roney, C., Kulkarni, P., Arora, V., Antich, P., Bonte, F., Wu, A., Mallikarjuana, N. N., Manohar, S., Liang, H. F., Kulkarni, A. R., Sung, H. W., Sairam, M., & Aminabhavi, T. M. (2005). Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J. Control. Release, 108(2-3), 193-214.
127. Ross, T. M., Martinez, P. M., Renner, J. C., Thorne, R. G., Hanson, L. R., & Frey, W. H. (2004). Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: A non-invasive treatment strategy for multiple sclerosis. J. Neuroimmunol., 151(1-2), 66-77.
128. Sah, H., & Lee, B. -J. (2006). Development of new microencapsulation techniques useful for the preparation of PLGA microspheres. Macromol. Rapid Commun., 27(21), 1845-1851.
129. Sakane, T., Akizuki, M., Yamashita, S., Nadai, T., Hashida, M., & Sezaki, H. (1991). The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: The relation to the lipophilicity of the drug. Chem. Pharm. Bull. (Tokyo), 39(9), 2456-2458.
130. Sakane, T., Tanaka, C., Yamamoto, A., Hashida, M., Sesaki, H., Ueda, H., Takagi, H. (1989). The effect of polysorbate 80 on brain uptake and analgesic effect of Dkyotorphin. Int. J. Pharm., 57(1), 77-83.
131. Sättler, M. B., Demmer, I., Williams, S. K., Maier, K., Merkler, D., Gadjanski, I., Stadelmann, C., Bähr, M., & Diem, R. (2006). Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp. Neurol., 201(1), 172-181.
132. Schizophrenia and Bipolar Mania Treatment - Geodon. Retrieved January 1, 2008, 2008, from http://www.geodon.com/
133. Schmader, K. E. (2002). Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin. J. Pain, 18(6), 350-354.
134. Schmidt, D., & Rogawski, M. A. (2002). New strategies for the identification of drugs to prevent the development or progression of epilepsy. Epilepsy Res., 50(1-2), 71-78.
135. Schmidt, J., Metselaar, J. M., Wauben, M. H. M., Toyka, K. V., Storm, G., & Gold, R. (2003). Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain, 126(8), 1895-1904.
136. Seltzer, Z., Dubner, R., & Shir, Y. (1990). A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain, 43(205-218), 205.
137. SEROQUEL - Home. Retrieved January 1, 2008, 2008, from http://www.seroquel.com
138. Shi, N., & Pardridge, W. M. (2000). Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. U. S. A., 97(13), 7567-7572.
139. Shi, N., Zhang, Y., Zhu, C., Boado, R. J., & Pardridge, W. M. (2001). Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U. S. A., 98(22), 12754-12759.
140. Silva, G. A. (2007). Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier. Surg. Neurol., 67(2), 113-116.
141. Song, B. -W., Vinters, H. V., Wu, D., & Pardridge, W. M. (2002). Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J. Pharmacol. Exp. Ther., 301(2), 605-610.
142. Song, C., & Leonard, B. E. (2005). The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav. Rev., 29(4-5), 627-647.
143. Sood, A., Beach, J. W., Webster, S. J., Terry, A. V., & Buccafusco, J. J. (2007). The effects of JWB1-84-1 on memory-related task performance by amyloid A.beta. transgenic mice and by young and aged monkeys. Neuropharmacology, 53(5), 588-600.
144. Stone, L. A., Smith, M. E., Albert, P. S., Bash, C. N., Maloni, H., Frank, J. A., & McFarland, HF. (1995). Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: Relationship to course, gender, and age. Neurology, 45(6), 1122-1126.
145. Sugawara, T., Tsurubuchi, Y., Agarwala, K. L., Ito, M., Fukuma, G., Mazaki-Miyazaki, E., Nagafuji, H., Noda, M., Imoto, K., Wada, K., Mitsudome, A., Kaneko, S., Montal, M., Nagata, K., Hirose, S., & Yamakawa, K. (2001). A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc. Natl. Acad. Sci. U. S. A., 98(11), 6384-6389.
146. Swainston, H. T., & L, G. K. (2004). Long-acting risperidone: A review of its use in schizophrenia. CNS Drugs, 18(2), 113-132.
147. Tanja, K., Gueanelle, L., Andreas, B., Jana, S., & Wolfgang, B. (2002). Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain, 125(Part 10), 2202-2212.
148. Thase, M. E. (2007). Molecules That mediate mood. N. Engl. J. Med., 357(23), 2400-2402.
149. Tischner, D., Weishaupt, A., van den Brandt, J., Müller, N., Beyersdorf, N., Ip, C. W., Toyka, K. V., Hünig, T., Gold, R., Kerkau, T., & Reichardt, H. M. (2006). Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain, 129(Part 10), 2635-2647.
150. Tober, C., Rostock, A., Rundfeldt, C., & Bartsch, R. (1996). D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol., 303(3), 163-169.
151. Treatment for Depression and Anxiety: Lexapro (Escilatopram Oxalate) Medication. Retrieved January 1, 2008, 2008, from http://www.lexapro.com
152. Treatment for Depression and Anxiety - Zoloft.com. Retrieved January 1, 2008, 2008, from http://www.zoloft.com
153. van Veelen, N. M., & Kahn, R. S. (1999). Dopamine, serotonin, and schizophrenia. Adv. Neurol., 80, 425-429.
154. Vyas, T. K., Babbar, A. K., Sharma, R. K., Singh, S., & Misra, A. (2006). Intranasal mucoadhesive microemulsions of clonazepam: Preliminary studies on brain targeting. J. Pharm. Sci., 95(3), 570-580.
155. Wallace, R. H., Wang, D. W., Singh, R., Scheffer, I. E., George, A. L., Jr., Phillips, H. A., Saar, K., Reis, A., Johnson, E. W., Sutherland G. R., Berkovic, S. F., & Mulley, J. C. (1998). Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel .β1 subunit gene SCN1B. Nat. Genet., 19(4), 366-370.
156. Wassef, A., Baker, J., & Kochan, L. D. (2003). GABA and schizophrenia: A review of basic science and clinical studies. J. Clin. Psychopharmacol., 23(6), 601-640.
157. Weinberger, D. R. (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry, 44(7), 660-669.
158. Welcome to the official site of LYRICA - Find more information about Nerve Pain, DPN, PHN and P. Retrieved January 1, 2008, 2008, from http://www.lyrica.com
159. White, H. S. (2003). Preclinical development of antiepileptic drugs: Past, present, and future directions. Epilepsia, 44(Suppl. 7), 2-8.
160. White, H. S., Wolf, H. H., Woodhead, J. H., & Kupferberg, H. J. (1998). The National Institutes of Health Anticonvulsant Drug Development Program: Screening for efficacy. Adv. Neurol., 76, 29-39.
161. Willner, P. (2005). Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology, 52(2), 90-110.
162. Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., & Woolsey, J. (2006). DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res., 34, D668-D672.
163. Wolfe, M. S. (2001). Secretase targets for Alzheimer's disease: Identification and therapeutic potential. J. Med. Chem., 44(13), 2039-2060.
164. Woolf, C. J. (2004). Dissecting out mechanisms responsible for peripheral neuropathic pain: Implications for diagnosis and therapy. Life Sci., 74(21), 2605-2610.
165. Yokoyama, S. -I., Ohishi, N., Shamoto, M., Watanabe, Y., & Yagi, K. (1997). Isolation and expression of rat interferon-β gene and growth-inhibitory effect of its expression on rat glioma cells. Biochem. Biophys. Res. Commun., 232(3), 698-701.
166. Yong, V. W., Giuliani, F., Xue, M., Bar-Or, A., & Metz, L. M. (2007). Experimental models of neuroprotection relevant to multiple sclerosis. Neurology, 68(Suppl. 3), S32-S37.
167. Ziemssen, T. (2005). Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis. J. Neurol., 252(Suppl. 5), V/38-V/45.